ClinicalTrials.gg
RecruitingNCT06749054Updated Apr 24, 2026

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

A Phase 2 interventional study of Oral Lenacapavir and Subcutaneous Lenacapavir in HIV-1-infection, sponsored by Gilead Sciences. Recruiting at 9 sites in 2 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug, lenacapavir (LEN). The study will assess the safety, tolerability, and efficacy of long-acting LEN when combined with other medicines in adolescents and children living with HIV-1 who weigh at least 35 kg and have been treated before for HIV-1. The study will also see how easy it is for participants to take LEN as injection or an oral pill.

The primary objectives are to evaluate the pharmacokinetics and safety of LEN in combination with optimized background regimen (OBR) in TE pediatric participants with HIV-1.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Body weight at screening ≥ 35 kg.
  • On a stable failing antiretroviral (ARV) regimen for > 8 weeks before screening and willing to continue the regimen until Day 1.
  • Plasma -1 RNA ≥ 400 copies/mL on at least 2 consecutive occasions spanning at least 6 months, including at screening.
  • Have previously changed their ARV regimen due to treatment failure.
  • ARV treatment options limited due to resistance, tolerability, , safety, drug access.
  • Able and willing to commit to taking LEN in combination with their OBR.
  • The following laboratory parameters at screening:

    1. Estimated (eGFR) ≥ 60 mL/min/1.73 m\^2 using Bedside Schwartz Formula.
    2. > 0.50 GI/L (> 500 cells/mm\^3).
    3. ≥ 85 g/L (> 8.5 g/dL).
    4. ≥ 50 GI/L (≥ 50,000/mm\^3).
    5. Hepatic transaminases ( and alanine aminotransferase) ≤ 5 × .
    6. Total ≤ 23 μmol/L (≤ 1.5 mg/dL) and direct bilirubin ≤ 7 μmol/L (≤ 0.4 mg/dL).

Key Exclusion Criteria:

  • ≤ 1 year.
  • An opportunistic illness requiring treatment within the 30 days prior to screening.
  • Evidence of active pulmonary or extra-pulmonary tuberculosis within 3 months prior to screening.
  • virus (HCV) antibody positive with detectable HCV RNA at screening.
  • virus (HBV) surface antigen (HBsAg) positive or HBV core antibody (antibody against hepatitis B core antigen (anti-HBc)) positive; if individual is HBsAg negative and anti-HBc positive but HBV DNA undetectable, individual may be enrolled.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    LEN

    Participants will receive oral LEN 600 mg on Days 1 and 2. Participants will also receive 2 doses of LEN 927 mg as subcutaneous (SC) injection on Day 1 and Week 26 along with their OBR per clinical practice. At the Week 52, participants will be given the option to receive SC LEN every 6 months while continuing their OBR for at least another 2 SC LEN doses in the extension phase.

    Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Optimized Background Regimen (OBR)

Interventions

  • Tablets administered without regard to food

    Also known as: GS-6207, Sunlenca®

  • Administered via subcutaneous injections

    Also known as: GS-6207, Sunlenca®

  • DrugOptimized Background Regimen (OBR)

    Optimized background regimen as prescribed by the Investigator

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Ctrough, W26 of Lenacapavir (LEN)

    Ctrough, W26 is defined as the plasma concentration at the end of the dosing interval at Week 26.

    Time frame: Week 26

  2. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26

    Time frame: First dose date up to Week 26

  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26

    Time frame: First dose date up to Week 26

Secondary outcomes

  1. PK Parameter: Cmax, D1-W26 of LEN

    Cmax, D1-W26 is defined as the maximum observed concentration of drug from Day 1 to Week 26.

    Time frame: Day 1 up to Week 26

  2. PK Parameter: AUC D1-W26 of LEN

    AUC D1-W26 is defined as the partial area under the concentration versus time curve from Day 1 to Week 26.

    Time frame: Day 1 up to Week 26

  3. Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52

    Time frame: First dose date up to Week 52

  4. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 52

    Time frame: First dose date up to Week 52

  5. Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 26 Based on the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm

    Time frame: Week 26

  6. Percentage of Participants with Plasma HIV-1 RNA < 50 Copies/mL at Week 52 Based on the US FDA-Defined Snapshot Algorithm

    Time frame: Week 52

  7. Change From Baseline in Clusters of Differentiation (CD4)+ Cell Counts at Week 26

    Time frame: Baseline, Week 26

  8. Change From Baseline in CD4+ Cell Counts at Week 52

    Time frame: Baseline, Week 52

  9. Percent Change From Baseline in CD4+ at Week 26

    Time frame: Baseline, Week 26

  10. Percent Change From Baseline in CD4+ at Week 52

    Time frame: Baseline, Week 52

  11. General Acceptability of Oral LEN as Assessed by Percentage of Participants With Acceptability Questionnaire Responses on Day 1

    To assess the acceptability of the study drug, the participants will complete questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale.

    Time frame: Day 1

  12. General Acceptability of Oral LEN as Assessed by Percentage of Participants With Acceptability Questionnaire Responses on Day 2

    To assess the acceptability of the study drug, the participants will complete questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale.

    Time frame: Day 2

  13. General Palatability of Oral LEN as Assessed by Percentage of Participants With Palatability Questionnaire Responses on Day 1

    To assess the palatability of the study drug, the participants will complete questionnaire including a question on general palatability of the assigned study drug on an ordinal 5-category scale.

    Time frame: Day 1

  14. General Palatability of Oral LEN as Assessed by Percentage of Participants With Palatability Questionnaire Responses on Day 2

    To assess the palatability of the study drug, the participants will complete questionnaire including a question on general palatability of the assigned study drug on an ordinal 5-category scale.

    Time frame: Day 2

07

Study locations

8 of 9 sites recruiting
  • Grady Health System, Ponce De Leon Center
    Atlanta, Georgia 30308, United States
    Recruiting
  • FAMCRU
    Cape Town, 7505, South Africa
    Recruiting
  • CRISMO Research Centre
    Germiston, 1401, South Africa
    Recruiting
  • Wits RHI Shandukani Research Centre CRS
    Johannesburg, 2038, South Africa
    Recruiting
  • Rahima Moosa Mother and Child Hospital
    Johannesburg, 2112, South Africa
    Recruiting
  • Clinical Research Institute of South Africa (CRISA)
    KwaDukuza, 4449, South Africa
    Recruiting
  • Durban International Clinical Research Site, Enhancing Care Foundation
    KwaZulu - Natal, 4093, South Africa
    Recruiting
  • Be Part Research Pty (Ltd)
    Paarl, 7626, South Africa
    Recruiting
  • Perinatal HIV Research Unit (PHRU)
    Soweto, 2013, South Africa
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 27, 2024
StartActual
Mar 26, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06749054
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Mar 26, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenacapavir

Start the discussion